CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma

American Journal of Pathology

Volumn 172, Issue 6, 2008, Pages 1650-1663

  Yoshizaki, Ayumi ^a   Iwata, Yohei ^a   Komura, Kazuhiro ^a   Ogawa, Fumihide ^a   Hara, Toshihide ^a   Muroi, Eiji ^a   Takenaka, Motoi ^a   Shimizu, Kazuhiro ^a   Hasegawa, Minoru ^b   Fujimoto, Manabu ^b   Tedder, Thomas F ^c   Sato, Shinichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BLEOMYCIN; CD19 ANTIGEN; HYALURONIC ACID; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; FIBROGENESIS; HISTOPATHOLOGY; HYPERGAMMAGLOBULINEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; LUNG FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS;

EID: 44849130732     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.071049     Document Type: Article

References (65)

1. LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N, Jablonska S, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988, 15:202-205
2. Okano Y: Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996, 22:709-735
3. Sato S, Fujimoto M, Hasegawa M, Takehara K: Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50:1918-1927
4. Gudbjornsson B, Hallgren R, Nettelbladt O, Gustafsson R, Mattsson A, af Geijerstam E, Totterman TH: Phenotypic and functional activation of alveolar macrophages. T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjogren's syndrome. Ann Rheum Dis 1994, 53:574-579
5. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L: Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005, 64:1233-1235
6. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666
7. Tedder TF, Poe JC, Fujimoto M, Haas KM, Sato S: The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun 2005, 8:55-90
8. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF: CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 1996, 157:4371-4378
9. Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF: CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997, 186:1923-1931
10. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K: Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643
11. Tsuchiya N, Kuroki K, Fujimoto M, Murakami Y, Tedder TF, Tokunaga K, Takehara K, Sato S: Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004, 50:4002-4007
12. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF: Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004, 41:1123-1133
13. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S: Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201
14. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462
15. Matsushita T, Fujimoto M, Hasegawa M, Matsushita Y, Komura K, Ogawa F, Watanabe R, Takehara K, Sato S: BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007, 127:2772-2780
16. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF: B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966
17. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD: Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001, 44:1359-1362
18. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K: Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999, 112:456-462
19. Yamamoto T: The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006, 297:333-344
20. Engel P, Zhou L-J, Ord DC, Sato S, Koller B, Tedder TF: Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995, 3:39-50
21. Ashcroft T, Simpson JM, Timbrell V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988, 41:467-470
22. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J: A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diag 2001, 3:55-61
23. Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol 1999, 162:7088-7094
24. Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K: Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J Rheumatol 1999, 26:2628-2634
25. Yamamoto T, Kuroda M, Nishioka K: Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000, 292:535-541
26. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, Iwamoto I: Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999, 104:5-11
27. Yaekashiwa M, Nakayama S, Ohnuma K, Sakai T, Abe T, Satoh K, Matsumoto K, Nakamura T, Takahashi T, Nukiwa T: Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med 1997, 156:1937-1944
28. Hawkins RA, Claman HN, Clark RA, Steigerwald JC: Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med 1985, 102:182-186
29. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003, 100:12319-12324
30. Nakagome K, Dohi M, Okunishi K, Tanaka R, Miyazaki J, Yamamoto K: In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax 2006, 61:886-894
31. Smith RE, Strieter RM, Phan SH, Lukacs N, Kunkel SL: TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. J Leukoc Biol 1998, 64:528-536
32. Segel MJ, Izbicki G, Cohen PY, Or R, Christensen TG, Wallach-Dayan SB, Breuer R: Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis. Am J Physiol 2003, 285:L1255-L1262
33. Rottem M, Mekori YA: Mast cells and autoimmunity. Autoimmun Rev 2005, 4:21-27
34. Cavaillon JM: Cytokines and macrophages. Biomed Pharmacother 1994, 48:445-453
35. Hu L, Dixit VD, de Mello-Coelho V, Taub DD: Age-associated alterations in CXCL1 chemokine expression by murine B cells. BMC Immunol 2004, 5:15-29
36. Taub D, Dastych J, Inamura N, Upton J, Kelvin D, Metcalfe D, Oppenheim J: Bone marrow-derived murine mast cells migrate, but do not degranulate, in response to chemokines. J Immunol 1995, 154:2393-2402
37. Lippert U, Artuc M, Grutzkau A, Moller A, Kenderessy-Szabo A, Schadendorf D, Norgauer J, Hartmann K, Schweitzer-Stenner R, Zuberbier T, Henz BM, Kruger-Krasagakes S: Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol 1998, 161:2600-2608
38. Kitaura J, Kinoshita T, Matsumoto M, Chung S, Kawakami Y, Leitges M, Wu D, Lowell CA, Kawakami T: IgE- and IgE+ Ag-mediated mast cell migration in an autocrine/paracrine fashion. Blood 2005, 105:3222-3229
39. Ishii Y, Yang H, Sakamoto T, Nomura A, Hasegawa S, Hirata F, Bassett DJ: Rat alveolar macrophage cytokine production and regulation of neutrophil recruitment following acute ozone exposure. Toxicol Appl Pharmacol 1997, 147:214-223
40. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC: Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002, 195:99-111
41. Johnson GB, Brunn GJ, Platt JL: Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol 2004, 172:20-24
42. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, Noble PW: Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005, 11:1173-1179
43. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E: Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279:7370-7377
44. Stern R: Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol 2004, 83:317-325
45. Stern R, Asari AA, Sugahara KN: Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006, 85:699-715
46. Matsushita T, Fujimoto M, Hasegawa M, Komura K, Takehara K, Tedder TF, Sato S: Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am J Pathol 2006, 168:812-821
47. Gruber BL, Marchese MJ, Kew RR: Transforming growth factor-beta 1 mediates mast cell chemotaxis. J Immunol 1994, 152:5860-5867
48. Waldmann H: Immunology: protection and privilege. Nature 2006, 442:987-988
49. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20:197-216
50. Marshak-Rothstein A: Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6:823-835
51. Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342
52. Barr TA, Brown S, Ryan G, Zhao J, Gray D: TLR-mediated stimulation of APC: distinct cytokine responses of B cells and dendritic cells. Eur J Immunol 2007, 37:3040-3053
53. Choe JY, Crain B, Wu SR, Corr M: Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. J Exp Med 2003, 197:537-542
54. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T: Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 2004, 109:784-789
55. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, Takeuchi O, Akira S, Takeishi Y, Kubota I: Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003, 108:2905-2910
56. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S: Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006, 33:275-284
57. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998, 25:308-313
58. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum levels of interleukin 4 (IL-4),. IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24:328-332
59. Sato S, Hanakawa H, Hasegawa M, Nagaoka T, Hamaguchi Y, Nishijima C, Komatsu K, Hirata A, Takehara K: Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000, 27:2838-2842
60. Valentini G, Baroni A, Esposito K, Naclerio C, Buommino E, Farzati A, Cuomo G, Farzati B: Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 2001, 21:210-217
61. Yazawa N, Fujimoto M, Sato S, Miyake K, Asano N, Nagai Y, Takeuchi O, Takeda K, Okochi H, Akira S, Tedder TF, Tamaki K: CD19 regulates innate immunity by the Toll-like receptor RP105 signaling in B lymphocytes. Blood 2003, 102:1374-1380
62. Rosen A, Casciola-Rosen L: Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999, 6:6-12
63. Casiano CA, Martin SJ, Green DR, Tan EM: Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996, 184:765-770
64. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Eric Greshwin M, Wick G: Endothelial cell apoptosis is a primary pathogeneic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785-792
65. Yamamoto T, Nishioka K: Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2004, 122:44-50